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Background: Many genetic diseases are due to defects in protein trafficking where the mutant protein is
recognized by the quality control systems, retained in the endoplasmic reticulum (ER), and degraded by the
proteasome. In many cases, the mutant protein retains function if it can be trafficked to its proper cellular location.
We have identified structurally diverse correctors that restore the trafficking and function of the most common
mutation causing cystic fibrosis, F508del-CFTR. Most of these correctors do not act directly as ligands of CFTR, but
indirectly on other pathways to promote folding and correction. We hypothesize that these proteostasis regulators
may also correct other protein trafficking diseases.
Methods: To test our hypothesis, we used stable cell lines or transient transfection to express 2 well-studied
trafficking disease mutations in each of 3 different proteins: the arginine-vasopressin receptor 2 (AVPR2, also known
as V2R), the human ether-a-go-go-related gene (KCNH2, also known as hERG), and finally the sulfonylurea receptor
1 (ABCC8, also known as SUR1). We treated cells expressing these mutant proteins with 9 structurally diverse
F508del-CFTR correctors that function through different cellular mechanisms and assessed whether correction
occurred via immunoblotting and functional assays. Results were deemed significantly different from controls by a
one-way ANOVA (p < 0.05).
Results: Here we show that F508del-CFTR correctors RDR1, KM60 and KM57 also correct some mutant alleles of
other protein trafficking diseases. We also show that one corrector, the cardiac glycoside ouabain, was found to
alter the glycosylation of all mutant alleles tested.
Conclusions: Correctors of F508del-CFTR trafficking might have broader applications to other protein trafficking
diseases.
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Many protein trafficking diseases are caused by muta-
tions that cause temperature sensitive misfolding
and can be partially corrected by incubation at low
temperature (< 30°C) or treatment with high concentra-
tions of osmolytes such as glycerol, trimethylamine
oxide or 4-phenylbutyrate [1-3]. However, most of these
are not feasible therapeutic strategies. Small molecule* Correspondence: david.thomas@mcgill.ca
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reproduction in any medium, provided the orcorrectors have recently been identified for several protein
trafficking diseases including cystic fibrosis (CF) [4-12].
Some of these correctors function as pharmacological
chaperones and bind directly to the mutant protein to
improve its folding [10,13]. Pharmacological chaperones
for CF are predicted to be specific for the cystic fibrosis
transmembrane conductance regulator (CFTR) and not
correct other mutant proteins unless they share structural
similarity with CFTR. Other correctors target cellular
pathways and act through proteostasis [14-19]. These
proteostasis regulators are predicted to correct diverse
protein trafficking diseases. The F508del-CFTR correctorsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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compounds that act on different cellular pathways. They
include the phosphodiesterase inhibitors KM57 and
KM60 [18], poly ADP-ribose polymerase (PARP) inhibi-
tors ABT-888 [14,20] and latonduine [15], the cardiac
glycoside ouabain [19], the cyclooxygenase inhibitor glafe-
nine [17], carbamazepine, a sodium channel blocker which
promotes proteasomal and autophagic degradation of
mutant proteins [21,22], and RDR1, a corrector that we
originally reported to act as a pharmacological chaperone
[12], but whose mechanism of action remains unclear
[23]. We also included the F508del-CFTR pharmaco-
logical chaperone VRT-325 [10,13]. Notably, VRT-325 has
been reported to correct other mutated proteins besides
CFTR [10].
We investigated mutants from a diverse set of well-
studied protein trafficking diseases including the nephro-
genic diabetes insipidus mutations V206D and L292P in
the arginine-vasopressin receptor 2 (AVPR2, also known
as V2R) [24,25], the LQTS2 mutations G601S and F805C
in the human ether-a-go-go-related gene (KCNH2, also
known as hERG) [26,27], and finally the persistent hyper-
insulinemic hypoglycemia of infancy (PHHI, also known
as congenital hyperinsulinism) mutations A116P and
V187D in the sulfonylurea receptor 1 (ABCC8, also
known as SUR1) [10,28,29], a component of the KATP
channel. All these proteins are localized to the plasma
membrane and have one or more glycosylation sites that
can be used to monitor their progression through the
secretory pathway by immunoblotting, where ER-retained
(core-glycosylated) proteins migrate faster than rescued
(complex-glycosylated) proteins. Additionally, there is cur-
rently no treatment for these diseases that addresses the
basic protein trafficking defect.
We show that RDR1 rescues a mutant of the only
other ATPase-binding cassette (ABC) protein related to
CFTR in our study, SUR1. Additionally, we show that
the phosphodiesterase inhibitors KM60 and KM57 res-
cue the trafficking of a hERG mutant. Finally, we show
that ouabain modifies the glycosylation of all mutants
tested, albeit without correcting the trafficking of pro-
teins other than CFTR. Our results provide impetus for
testing F508del-CFTR correctors on other trafficking
disease mutants, which could generate new leads with
therapeutic benefit to several rare diseases.
Methods
Cell lines and constructs
The GFP-tagged V2R WT clone was generated by site-
directed mutagenesis of plasmid V2R-V206D.GFP, kindly
provided by Dr. Peter Deen (NCMLS, The Netherlands),
using the primers 50-CCGTCGCACCTATGTTACCTG
GATTGCCC-30 and 50-GGGCAATCCAGGTAACATAG
GTGCGACGG-30. HA-FLAG-tagged V2R WT and HA-tagged V2R L292P in pcDps, kindly provided by Dr.
Torsten Schöneberg (University of Leipzig, Germany),
were sub-cloned into pcDNA3.1 using BglII and SpeI
sites in pcDps and BamHI and XbaI sites in pcDNA3.1
(WT) or BglII and XhoI sites (L292P). HEK cells stably
expressing HA-tagged hERG G601S [30] were kindly
provided by Dr. Eckhard Ficker (Case Western Reserve
University, U.S.A.). HA-tagged hERG F805C mutant and
WT plasmids have been described previously [31].
FLAG-tagged hamster SUR1 WT, A116P and V187D
mutants and rat Kir6.2 plasmids have been described
previously [32].
Transfection and compound treatment
HeLa cells were seeded at a density of 8.0x10^6 cells/
flask and transiently transfected with 18 μg of plasmid
and 63 μl of Fugene HD overnight. The following day,
the cells were trypsinized and seeded into 6-well plates
at 1.0-1.5x10^6 cells/well. The following day, the cells
were treated with compounds or vehicle at a final
DMSO concentration of 0.1% for 24 h. HEK cells stably
expressing 3HA-hERG G601S were seeded in 6-well
dishes as above and treated with compounds for 48 h.
Immunoblotting
Cells were harvested in RIPA buffer [150 mM NaCl,
20 mM Tris, 0.01% SDS, 0.08% sodium deoxycholate, 1%
Triton-X-100, pH 8.0 with protease inhibitors (Roche)].
Equal amounts of protein were separated by SDS-PAGE
and transferred onto nitrocellulose. Blots were blocked
in PBST (137 mM NaCl, 2.68 mM KCl, 9.31 mM
Na2HPO4, 2.45 mM KH2PO4, pH 7.4, containing 0.1%
Tween-20) containing 5% skim milk and probed with
appropriate primary antibodies (rabbit anti-hERG, Cal-
biochem; SUR1: mouse anti-FLAG M2, Sigma; V2R
V206D: mouse anti-GFP, Roche; V2R L292P: mouse
anti-HA, Covance). The blots were washed in PBST and
probed with HRP-conjugated secondary antibodies.
Chemiluminescent substrates were added and the blots
were exposed to film.
Densitometry
The relative levels of each HERG glycoform for selected
treatments were estimated by densitometry using Photo-
shop (Adobe Inc.). The values reported are expressed as
means +/− SD (n = 3).
Patch clamping (hERG G601S)
Whole-cell currents were recorded from HEK hERG
G601S cells after 48 h of treatment with compounds. An
Alembic VE-2 patch clamp amplifier (Alembic Instru-
ments Inc., Montreal) that provides full series resistance
compensation was used to record whole-cell currents.
The bath solution contained 137 mM NaCl, 4 mM KCl,
Figure 1 Some F508del-CFTR correctors correct the trafficking of hERG G601S. Representative immunoblots are shown for decreasing
concentrations of ABT-888 and glafenine (A), ouabain (B), sildenafil, KM60, and KM57 (C), RDR1 (D), telenzepine and latonduine (E). In all blots,
negative control (DMSO) and positive controls (astemizole; VRT-325; DMSO, 29°C) are shown. Arrows indicating core-glycosylated hERG G601S,
and complex-glycosylated hERG G601S, which represents the corrected protein, are shown. Tubulin is shown as a loading control. (F)
Densitometric quantitation of core and complex-glycosylated bands for selected treatments is shown. Error bars indicate SD (n = 3).
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Figure 2 F508del-CFTR trafficking correctors have mixed effects
on the trafficking of wild type hERG. (A) Representative blot
showing wt hERG treated with selected trafficking correctors as
labeled above the immunoblot. Arrows indicate core and complex-
glycosylated hERG. Tubulin serves as a loading control. (B) siRNA
knockdown of PDE5A does not correct the trafficking of hERG
G601S. Top: hERG G601S cells treated with vehicle (DMSO), 1 μM
astemizole as a positive control, siRNA transfection reagent alone
(HiPerfect), non-targeting siRNA, or two separate wells transfected
with 25 nM siRNA against PDE5A. Arrows indicate core and
complex-glycosylated hERG. Middle: PDE5A expression levels in each
of the samples described. Bottom: Tubulin serves as a loading
control.
Figure 3 Ouabain treatment induces an intermediate hERG
G601S glycosylation state. (A) Representative blot showing hERG
G601S treated with increasing concentrations of ouabain in the
absence (−) and presence of endoglycosidase enzymes Endo H (H),
PNGase F (F), as indicated. Treatment with vehicle (DMSO) and
astemizole are shown as negative and positive controls for
correction. Core, intermediate, and complex-glycosylated hERG are
marked by arrows. (B) Tubulin is shown as a loading control.
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10 mM HEPES (pH 7.4). Patch pipettes were made from
borosilicate glass with a resistance of 3–6 megaohms.
Intracellular pipette solution contained 130 mM KCl,
1 mM MgCl2, 5 mM EGTA, 5 mM MgATP and 10 mM
HEPES (pH 7.2). Cells were held at a potential of
−80 mV. hERG tail currents were evoked by 4 s steps
ranging from −60 to +50 mV in increments of 10 mV,
with each step followed by a repolarizing step to -50 mV
for 2 s. Data were collected and analyzed with Clampex
8 and Prism software.Rubidium efflux (SUR1 mutants)
COSm6 cells were plated onto 6-well plates and transi-
ently transfected with 0.6 μg SUR1 and 0.4 μg Kir6.2
plasmids and 3 μl Fugene overnight. The following day,
the cells were treated with compounds or vehicle for
24 h. Cells were incubated for an additional 12 h in cul-
ture medium containing 86RbCl (1 μCi/ml); during this
period, compounds were present in the first 10 h fol-
lowed by a 2-h washout. Before measurement of 86Rb+
efflux, cells were incubated for 30 min at room
temperature in Krebs-Ringer solution (118 mM NaCl,
2.5 mM CaCl2.H2O, 1.2 mM KH2PO4, 4.7 mM KCl,
25 mM NaHCO3, 1.2 mM MgSO4, 10 mM HEPES, pH
7.4) with metabolic inhibitors (2.5 μM oligomycin and
1 mM 2-deoxy-D-glucose) to open the channel. At
selected time points the solution in the well was col-
lected and fresh solution added. At the end of a 40-min
period, the cells were lysed. The 86Rb+ in the collected
solution and the cell lysate was counted. The percentage
efflux at each time point was calculated as the cumula-
tive counts in the collected solution divided by the total
counts from the solutions and the cell lysate.
Cyclic AMP assays
Cyclic AMP assays (Sigma-Aldrich) were performed
according to the manufacturer’s directions. Briefly, cells
transfected with V2R plasmids were seeded at 3.0x10^5
cells/well in 24-well dishes and treated the following day
for 24 h with compound, in quadruplicate. The following
day, the cells were washed with warm PBS and treated
with 250 μM IBMX for 10 min to inhibit any phospho-
diesterase activity [33]. The medium was aspirated and
replaced with either fresh medium containing 0.1%
Figure 4 Few F508del-CFTR correctors correct the trafficking of
hERG F805C. (A) A representative immunoblot is shown for cells
transfected with vector control (vector), wt hERG (wt), and hERG
F805C treated with negative control (DMSO), positive control (DMSO
29°C), astemizole, VRT-325, decreasing concentrations of KM60,
KM57, and ouabain (ouab). Arrows indicate core and complex-
glycosylated hERG F805C. Tubulin is shown as a loading control. (B)
A representative immunoblot is shown for cells transfected with
vector control (vector), wt hERG (wt), and hERG F805C treated with
negative control (DMSO), positive control (DMSO 29°C), astemizole,
VRT-325, decreasing concentrations of RDR1 and glafenine. Arrows
indicate core and complex-glycosylated hERG F805C. Tubulin is
shown as a loading control.
Sampson et al. Orphanet Journal of Rare Diseases 2013, 8:11 Page 5 of 12
http://www.ojrd.com/content/8/1/11DMSO (unstimulated control, in duplicate) or fresh
medium containing 100 nM DDAVP (stimulated, in
duplicate) for 10 min to stimulate V2R at the cell surface
[33]. Cells were washed with PBS and lysed in 110 μl of
100 mM HCl at room temperature. Supernatants were
collected and centrifuged. 50 μl of the supernatant were
used in the assay.
Statistical analyses
Statistical analysis was performed as described in the Figure
legends. P-values < 0.05 were considered significant.
Results and discussion
We tested whether F508del-CFTR correctors could
restore hERG G601S trafficking and function. As shownin Figure 1, several correctors including KM57, KM60,
glafenine, ouabain, and latonduine modified the glycosy-
lation of this hERG mutant as judged by the appearance
of slower-migrating, complex-glycosylated forms of the
protein, indicating partial rescue. Treatment with glafe-
nine, KM60 and KM57 resulted in the most prominent
complex-glycosylated forms of HERG G601S, while
latonduine treatment appeared to yield slightly less res-
cue. Low temperature, VRT-325 and the hERG channel
blocker astemizole served as positive controls [10,26].
Interestingly, low temperature treatment produced an
additional slower migrating species that was not present
in the other positive controls (Figure 1A-E). Treatment
with the cardiac glycoside ouabain, a known inhibitor
of trafficking of the wild type hERG channel [34] (see
also Figure 2A), produced an intermediate glycoform
(Figure 1B, Figure 3). Densitometric quantitation of
some of the treatments is shown in Figure 1F. We also
tested these correctors on the trafficking of the hERG
F805C mutant. Unlike hERG G601S, the F805C mutant
was only corrected by low temperature and an inter-
mediate glycoform was produced with ouabain treat-
ment (Figure 4). Given that sildenafil, KM60 and KM57
are all phosphodiesterase inhibitors, and KM60 and
KM57 were more potent correctors of hERG G601S, we
chose to pursue only KM60 and KM57 in our study. To
determine if correction resulted in a functional hERG
G601S polypeptide, we used patch clamp recording
(Figure 5). A short (1 hr) washout of the correctors was
necessary to observe an increase in hERG tail currents
(Figure 5). Exposure and washout of KM57 (Figure 5C),
KM60 (Figure 5D), glafenine (Figure 5E), and astemizole
(Figure 5B) all resulted in increased hERG G601S tail
currents (Figure 5F). DMSO vehicle (0.1%) served as a
negative control (Figure 5A). Treatment and washout of
KM57 resulted in a statistically significant increase in
hERG G601S tail currents above the DMSO control
(Figure 5F). Since a washout step was necessary to ob-
serve tail currents, the mechanism used by these correc-
tors may be through direct binding to, and inhibition of,
the mutant channel [35]. Alternatively, KM57 and
KM60 may be acting through a proteostasis regulator.
To test this hypothesis, we used siRNA knockdown of
PDE5A, the purported target of KM60 and KM57.
Interestingly, knockdown of PDE5A did not result in an
increase in hERG G601S trafficking (Figure 2B). Add-
itionally, treatment of wild type hERG with these cor-
rectors reduced the amount of complex-glycosylated
mature hERG detected by immunoblotting (Figure 2A).
In contrast, low temperature treatment of wild type
hERG induced significantly greater amounts of both the
core and complex-glycosylated forms of the protein, as
would be expected due to the more favorable conditions
for protein folding [19]. These results suggest that
Figure 5 F508del-CFTR correctors result in functional hERG G601S channels. Representative patch clamping traces are shown for vehicle-
treated cells (A), astemizole treatment and washout (B), KM57 treatment and washout (C), KM60 treatment and washout (D), and glafenine
treatment and washout (E). Quantitative analysis of the tail currents is shown in (F). Only KM57 treatment resulted in a significant increase in tail
currents using one-way ANOVA and Bonferroni’s multiple comparison test (p =0.0131). Numbers below the treatments indicate n.
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Figure 6 F508del-CFTR correctors correct the trafficking of SUR1 mutants V187D and A116P. Representative immunoblots are shown for
SUR1 V187D (A-C) and SUR1 A116P (D-F). Representative immunoblot for cells expressing SUR1 V187D treated with decreasing concentrations of
ouabain (ouab), KM57, and RDR1 (A), KM60, ABT-888, and latonduine (latond) (B), glafenine and carbamazepine (carbam) (C). Representative
immunoblot for cells expressing SUR1 A116P treated with 10% glycerol (glycerol), decreasing concentrations of ouabain and glafenine (D),
carbamazepine (carbam), KM57, and KM60 (E), latonduine, RDR1, ABT-888 (F). In all blots, lanes expressing vector controls (vector), Kir6.2 in the
absence of SUR1 (−), and wild type SUR1 (wt) are shown. Lanes where Kir6.2 and SUR1 V187D or SUR1 A116P are expressed are indicated by a
line above the corresponding lanes. Each blot has a vehicle control (DMSO) and positive controls (glibenclamide; DMSO, 29°C). Arrows indicate
core-glycosylated SUR1 protein (core), complex-glycosylated SUR1 protein (complex, indicating rescue). Tubulin is shown as a loading control. In
panels A-C, an asterisk indicates a non-specific band.
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Figure 7 The F508del-CFTR corrector RDR1 improves the function of the SUR1 A116P mutant. (A) Representative 86Rb+ efflux profiles from
COS cells transiently transfected with SUR1 A116P and wt Kir6.2 and treated with 0.1% DMSO, 300μM tolbutamide (a reversible sulfonylurea) or
10μM RDR1 as described in the METHODS. Non-transfected cells (unt) and cells transiently transfected with wt SUR1 and Kir6.2 (SURwt) served as
controls. Each data point is the average of triplicates performed in the same experiment with the exception of RDR1-treated group (RDR1) in
which each data point is the average of six samples. Error bars indicate S.E.M. (B) Comparison of % 86Rb+ efflux at the 40-min time point in cells
treated with different compounds. Only RDR1 resulted in significant improvement of channel activity. Each data point is the mean ± S.E.M. (n = 7)
from 4 independent experiments; *, p < 0.05 compared to DMSO treated group by one-way ANOVA and Dunnett’s post-hoc test.
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regulator other than PDE5A to affect hERG trafficking.
We next tested the SUR1 mutants V187D and A116P
for correction with F508del-CFTR correctors. Treatment
with several correctors yielded the complex-glycosylated
form of these mutants, indicating partial rescue (Figure 6).
To determine whether correction of the SUR1 mutants
leads to functional recovery of KATP channels, we per-
formed 86Rb+ efflux assays to assess channel activity inintact cells in response to metabolic inhibition (Figure 7).
In contrast to cells expressing wild type SUR1 protein,
those expressing the SUR1 A116P mutant showed only
low levels of channel activity due to loss of surface expres-
sion after treatment with the DMSO control. Exposing
A116P-expressing cells to the reversible sulfonylurea drug
tolbutamide for > 24 h followed by a washout 2 h prior to
the assay led to almost complete recovery of channel
activity, as reported previously [32]. Among the correctors
Figure 8 V2R mutants show limited correction upon F508del-CFTR corrector treatment. Representative blots are shown for V2R V206D
(A-C) and V2R L292P (D-F). Representative immunoblot for cells expressing V2R V206D treated with decreasing concentrations of ouabain (ouab),
10nM ABT-888, decreasing concentrations of RDR1 (RDR1), and glafenine (glaf) (A); ABT-888 (ABT), ouabain (ouab), KM60, and latonduine (Lat) (B);
KM57 (C). Representative immunoblot for cells expressing V2R L292P treated with decreasing concentrations of ouabain (ouab), KM60, KM57,
RDR1 (D); ABT-888 (ABT888), latonduine (Lat), and glafenine (E); carbamazepine (F). In all blots, lanes expressing vector controls (vector), and wild
type V2R (wt) are shown. A line above the corresponding lanes indicates where V2R V206D or V2R L292P is expressed. Each blot has a vehicle
control (DMSO or DMSO 0.1%) and a positive control (DMSO, 29°C). For V2R V206D, two other positive controls are also included (1% DMSO,
glycerol). In (A-C), an arrow indicates core glycosylated V2R protein (core), a bracket indicates complex-glycosylated V2R protein (complex,
indicating rescue), an arrowhead indicates nonglycosylated protein (nonglycosylated), and a star indicates GFP. In (D-F), a black arrow indicates
mutant core glycosylated monomer, a black bracket indicates mutant complex-glycosylated monomer, and a black arrowhead indicates mutant
dimer. The same symbols are also shown in gray to indicate the wild type V2R protein, which has a slightly slower mobility on SDS-PAGE. In all
blots tubulin is shown as a loading control.
Sampson et al. Orphanet Journal of Rare Diseases 2013, 8:11 Page 9 of 12
http://www.ojrd.com/content/8/1/11
Figure 9 F508del-CFTR correctors do not functionally correct V2R mutants. Cyclic AMP accumulation assays are shown for cells expressing
V2R V206D (A) or V2R L292P (B) treated with correctors for 24 h. Data shown are means ± S.E.M. (n = 3 independent experiments). None of the
compound treatments were statistically significant from the DMSO control with a one-way ANOVA.
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RDR1 were tested for their effects on functional recovery
of the mutant channel. Only RDR1 improved channel
function significantly (Figure 7 and data not shown). We
previously reported RDR1 as a pharmacological chaperone
for F508del-CFTR that binds to and stabilizes the first
nucleotide-binding domain (NBD1) against thermal
denaturation [12]. However, additional studies since then
suggest that RDR1 does not exert its effect through NBD1
[23], although RDR1 may act still as a pharmacological
chaperone for F508del-CFTR by affecting other regions of
the protein. Interestingly, sulfonylureas correct the traf-
ficking of A116P and V187D mutants by binding to sites
outside the affected domain in SUR1, and possibly also
with a weak affinity site in Kir6.2 [36]. The mechanism ofTable 1 F508del-CFTR corrector compounds show distinct pro
Corrector CFTR F508del hERG G601S hERG F805C
VRT-325 + + -
Glycerol + ND ND
29°C ++ + +
KM60 + + -
KM57 +/− ++ -
ABT-888 + - ND
Glafenine + + -
RDR1 + - -
Ouabain + +/−* +*
Carbamazepine + - ND
Latonduine + +/− -
Astemizole ND + -
Glibenclamide ND ND ND
A qualitative assessment of correction as determined by glycosylation status in imm
compound, where “-“ indicates no correction observed, “+/−“ indicates slight correc
and “ND” indicates not determined. Asterisks indicate that an intermediate glycofor
included as positive controls for correction of hERG G601S and SUR1 mutants, respcorrection employed by RDR1 may be similar to that pro-
posed for sulfonylureas, perhaps mediated by binding at a
different site in SUR1. Alternatively, RDR1 may be acting
as a proteostasis regulator through an unidentified protein
that exerts its effects on both SUR1 and CFTR.
We also tested these correctors on the V2R mutants
L292P and V206D (Figures 8 and 9). Although several
correctors increased the trafficking of V2R V206D from
ER to the Golgi compartment as evidenced by the
appearance of complex-glycosylated forms of the protein
(Figure 8A-C), none of them corrected V2R function
following stimulation with a vasopressin analog (DDAVP)
(Figure 9). The positive controls (1% DMSO and 29°C)
increased cAMP production above the vehicle control
with the V2R V206D mutant; however, this difference wasfiles of correction for other ER-retained proteins
SUR1 A116P SUR1 V187D V2R L292P V2R V206D
- ND - ND
+ ND ND +/−
+ + ++ ++
+ + - +
+/− - - +/−
+ + - +
+ - - -
+ + - -
+ + + +
- +/− - ND
+ ++ +/− +
ND ND ND ND
++ ++ ND ND
unoblotting is shown for each mutation following treatment with a corrector
tion, “+” and “++” indicate more and best correction observed, respectively,
m was observed, but no correction. Astemizole and glibenclamide were
ectively.
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V2R L292P protein were slightly less amenable to correc-
tion by F508del-CFTR correctors than the V206D allele
(Figure 8D-F). None of the correctors yielded functional
correction upon stimulation (Figure 9B); however, incuba-
tion at 29°C resulted in approximately 2-fold more cAMP
than at 37°C (Figure 9B). This increase was not statistically
significant. These results contrast with previously pub-
lished results using COS cells where low temperature
preincubation increased V2R function significantly [25].
The lack of functional correction may be attributed to the
use of different cell types, or to the mutant proteins not
reaching the cell surface. This latter possibility seems less
likely as recent work by Robben et al. shows that intracel-
lular V2R can induce signaling in response to DDAVP
stimulation [37].
The results of immunoblotting studies are summarized
in Table 1. Only ouabain treatment altered the glycosyla-
tion of all mutants. RDR1 correction was the most
protein-specific as it only corrected the trafficking of
SUR1, the protein structurally related to CFTR in our
test set [38]. However, the other correctors did appear to
be partially allele-specific. They corrected at least one
protein besides F508del-CFTR, but not necessarily both
mutant alleles of the same protein.
Among the 9 correctors tested, only the cardiac glyco-
side ouabain altered the glycosylation of all mutant alleles
for these three different ER-retained proteins. The only
condition that corrects all mutant alleles is incubation at
low temperature. Interestingly, when the transcriptional
signatures of ouabain and low temperature are compared,
they show significant overlap [19], which may account for
the altered glycosylation state of ER-retained mutant pro-
teins. Although the exact mechanism employed by oua-
bain to elicit trafficking correction of F508del-CFTR has
not been elucidated, it is known to inhibit the Na+/K +
ATPase [39]. The inhibition of Na+/K + ATPase by
ouabain leads to intracellular calcium fluctuations and
altered glycosylation [40], which, together, could allow ER-
retained proteins to escape ER-related protein quality con-
trol mechanisms. Except for F508del-CFTR, ouabain does
not lead to functional correction of the two V2R traffick-
ing mutants that we tested. This discrepancy might be due
to the proteins escaping the ER, but not reaching the cell
surface where they function. Alternatively, ouabain may
not elicit enough correction for a functional response to be
detected; suggesting that further optimization of its chem-
ical scaffold or of the optimal dose would be necessary.
Conclusions
Taken together, the results provide a compelling case for
testing novel F508del-CFTR correctors on mutated
proteins in other trafficking diseases. Utilizing the hits
identified in high throughput screens for correctors ofF508del-CFTR can accelerate the development of correc-
tors for the protein trafficking defect underlying other
genetic diseases. A deeper understanding of the targets and
mechanisms of action of proteostasis regulators will also be
important in the development of these therapeutics.
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